SureTrader SureTrader
Home > Boards > US OTC > Cannabis >

Nemus Bioscience, Inc. (NMUS)

NMUS RSS Feed
Add NMUS Price Alert      Hide Sticky   Hide Intro
Moderator: MasterBlastr
Search This Board:
Last Post: 12/7/2016 5:56:31 PM - Followers: 62 - Board type: Free - Posts Today: 0

 

NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; and NB1222 used for treating chemotherapy induced nausea and vomiting. Its products under research comprise NB3111 for the treatment of methicillin-resistant Staphylococcus aureus, as well as NB2111 for use in treating chemotherapy induced peripheral neuropathy. The company was founded in 2012 and is headquartered in Costa Mesa, California.

NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the  under the symbol NMUS.

Company website: http://www.nemusbioscience.com/home.html

Filings and disclosure with Level 2 quotes:  http://www.otcmarkets.com/stock/NMUS/quote

Contact:

(949) 396-0330
E-MAIL: HELLO@NEMUSBIO.COM
600 ANTON BLVD, SUITE 1100, COSTA MESA, CA 92626


 

Nemus Bioscience (NMUS) Presentation (47 minutes):  
https://www.youtube.com/watch?v=tYV2PEaj6os

Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 12th, 2016: 
http://s2.q4cdn.com/753474459/files/doc_presentations/2016/Rodman-Conf-September-2016_FINAL.pdf

Interview with CEO - CMO Dr. Brian Murphy, MD,MPH,MBA  (register for free for complete text) 
http://seekingalpha.com/article/3478116-nemus-interview-ceo-dr-brian-murphy


Major press releases:

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions -


Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy


Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)

 

Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model

 

Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.


NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 


CANNAINVESTOR Magazine Top 20 Cannabis Stocks 

 

NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference 

 

NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients 

 

NEMUS Bioscience CEO to Present at BIO CEO & Investor Conference 

 

NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development 

 

Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN) 

 

NMUS Security Details

Share Structure - as of Nov 28, 2016
Source: otcmarkets.com

Authorized Shares: 236,000,000
Outstanding Shares: 
20,798,163
      - Restricted  13,594,621
    - Unrestricted   7,546,042


Transfer Agent: Clear Trust, LLC

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NMUS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 12/06/2016 08:18:38 AM
NMUS News: Notice of Effectiveness (effect) 12/06/2016 06:01:42 AM
NMUS News: Securities Registration Statement (s-1) 11/22/2016 04:49:44 PM
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/09/2016 04:52:54 PM
NMUS News: Quarterly Report (10-q) 11/09/2016 04:52:07 PM
PostSubject
#531  Sticky Note NMUS - Nemus Bioscience, Inc. quick DD MasterBlastr 11/10/16 12:40:30 PM
#878   Senate Clears Bill to Ease FDA Drug and MasterBlastr 12/07/16 05:56:31 PM
#877   BASH THIS ILLIQUID SCAM SUB PENNY SOON taubytaub 12/07/16 10:32:10 AM
#876   It was filed 8:18 in the morning - MasterBlastr 12/06/16 11:10:01 PM
#875   Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 4pm. a surfer 12/06/16 10:30:04 PM
#874   They will beat down their door, and they MasterBlastr 12/06/16 02:45:34 PM
#873   These guys are doing the raises the right MasterBlastr 12/06/16 02:44:53 PM
#872   They are trying. It's a legit group. There's Vinpat 12/06/16 02:38:33 PM
#871   I think the company is executing, if you MasterBlastr 12/06/16 02:29:51 PM
#870   If you don't like the stock don't buy Vinpat 12/06/16 01:11:48 PM
#869   Bash this scam taubytaub 12/06/16 11:55:07 AM
#868   5k slightly above CDEL and 10k below CDEL. Gutts2318 12/06/16 10:35:27 AM
#867   Guess I will bid down there too. Doesn't Gutts2318 12/06/16 10:26:01 AM
#866   CDEL showing his hand. The MM that was Gutts2318 12/06/16 10:25:04 AM
#865   Don't think they wants to keep being a Gutts2318 12/06/16 10:13:59 AM
#864   Thanks I have updated the I-Box . . . MasterBlastr 12/05/16 04:05:27 PM
#863   NMUS updated SS on otcmarket.com on Nov 28th Gutts2318 12/05/16 03:34:28 PM
#862   Did you find a change in O/S or MasterBlastr 12/05/16 03:29:56 PM
#861   Need MM CDEL to be active again for Gutts2318 12/05/16 02:34:45 PM
#860   Sounds like a plan . . . MasterBlastr 12/05/16 01:27:48 PM
#859   I will be bidding in lower 30s. Got Gutts2318 12/05/16 01:26:27 PM
#858   Next money to move this won't be from MasterBlastr 12/05/16 01:18:50 PM
#857   no more pulse left in this stock until Gutts2318 12/05/16 12:40:44 PM
#856   pre-IND meeting with the FDA? MasterBlastr 12/04/16 11:16:56 PM
#855   "In preparing for a pre-IND meeting with the MasterBlastr 12/04/16 11:16:08 PM
#854   This news received received widespread distribution within the MasterBlastr 12/04/16 10:06:31 PM
#853   PCG Advisory - link to Dec 1 news MasterBlastr 12/04/16 10:02:34 PM
#852   Floor does seem to be around .4 for afterhoursearnings 12/01/16 08:38:44 PM
#851   Lmao no CMIH 12/01/16 02:46:15 PM
#850   Thanks - news isn't showing up (yet) on MasterBlastr 12/01/16 11:15:26 AM
#849   News out today. Gutts2318 12/01/16 10:53:10 AM
#848   Nemus Bioscience Announces Milestones in the Development of Gutts2318 12/01/16 10:52:25 AM
#847   .04 coming taubytaub 12/01/16 10:37:32 AM
#846   The only flaw I see is the flaw Emptyhead 12/01/16 10:34:18 AM
#845   They have a floor of .40 and thats MasterBlastr 12/01/16 10:02:46 AM
#844   Are u hoping for an invite to the Emptyhead 12/01/16 10:00:59 AM
#843   Drug companies take their own sweet time . MasterBlastr 12/01/16 09:39:38 AM
#842   Old news. Yawn taubytaub 12/01/16 08:06:23 AM
#841   Nemus Bioscience Announces Presentation of NB1111 Impact on MasterBlastr 12/01/16 06:58:05 AM
#840   Nice. Yea 40's are clear support CMIH 12/01/16 01:05:31 AM
#839   I will be contacting IR in the next MasterBlastr 11/30/16 01:16:15 PM
#838   Somewhat reminds me of VPO* before it made jjr04001 11/30/16 10:38:35 AM
#837   No cash on hand lol CMIH 11/29/16 03:49:52 PM
#836   SLAP IT taubytaub 11/29/16 12:55:29 PM
#835   47's up! CMIH 11/29/16 12:51:21 PM
#834   Looking good today CMIH 11/29/16 11:55:54 AM
#833   Good . . . stick around. MasterBlastr 11/29/16 10:17:43 AM
#832   Like I said, I can assure you, should Emptyhead 11/29/16 10:16:05 AM
#831   What that you, dumping out your .38 from MasterBlastr 11/29/16 10:11:01 AM
#830   A final wringing out and bottoming of the Emptyhead 11/29/16 10:08:00 AM
#829   Looks that that was the final wringing out MasterBlastr 11/29/16 09:53:25 AM
PostSubject